FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296468> ?p ?o ?g. }

• W4367296468 abstract "<h3>Objective:</h3> Assess use of rimegepant and other medications for acute treatment of migraine, as well as frequency of moderate or severe migraine days on scheduled and nonscheduled rimegepant dosing days. <h3>Background:</h3> Rimegepant is an orally administered small molecule CGRP receptor antagonist and is the only medication approved for both acute and preventive treatment of migraine. <h3>Design/Methods:</h3> This 52-week open-label extension phase of a 12-week, phase 2/3, randomized, double-blind, placebo-controlled study of rimegepant for the preventive treatment of migraine (NCT03732638) included adults aged ≥18 years with a history of 4–18 moderate to severe monthly migraine attacks. Subjects completing 12 weeks of double-blind treatment with rimegepant 75 mg or placebo every other day (QOD) could continue with open-label rimegepant 75 mg scheduled QOD for preventive treatment of migraine over 52 weeks. On nonscheduled rimegepant dosing days, subjects could take rimegepant 75 mg up to once per day as needed for acute treatment. Subjects received 30 rimegepant tablets per month. Subjects could also use other medications for the acute treatment of migraine on scheduled and nonscheduled dosing days if needed. Months were defined as 4-week intervals. <h3>Results:</h3> Through 52 weeks, subjects used rimegepant a mean (SD) of 14.2 (1.90) days per month. On scheduled and nonscheduled rimegepant dosing days over 52 weeks, mean (SD) moderate or severe migraine days per month were 1.4 (1.71) and 1.4 (1.63), respectively, and mean (SD) other acute migraine medication days per month were 0.6 (1.09) and 0.6 (1.08), respectively. On nonscheduled rimegepant dosing days, subjects used rimegepant as an acute migraine medication a mean (SD) of 1.1 (1.53) days per month and rimegepant plus other acute migraine medication 0.2 (0.59) days per month. <h3>Conclusions:</h3> The monthly frequency of moderate or severe migraine days and use of other acute migraine medications was low and consistent between scheduled and nonscheduled rimegepant dosing days. <b>Disclosure:</b> Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alder Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Currax Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for electroCore. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundbeck Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher Smith. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/AbbVie. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven . Susan Hutchinson has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific . Susan Hutchinson has received publishing royalties from a publication relating to health care. Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Vorso. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Theranica. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Pavlovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NINDS. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from Veterans Administration. The institution of Dr. Lipton has received research support from NIH. Dr. Lipton has received publishing royalties from a publication relating to health care. Dr. Jensen has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Jensen has stock in Biohaven Pharmaceuticals. Alexandra Thiry has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Alexandra Thiry has received stock or an ownership interest from Biohaven Pharmaceuticals. Lisa Kamen has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc.. Lisa Kamen has received stock or an ownership interest from Biohaven Pharmaceuticals, Inc.. Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care." @default.
• W4367296468 created "2023-04-29" @default.
• W4367296468 creator A5001453416 @default.
• W4367296468 creator A5018036182 @default.
• W4367296468 creator A5031918001 @default.
• W4367296468 creator A5032171459 @default.
• W4367296468 creator A5054082461 @default.
• W4367296468 creator A5055769971 @default.
• W4367296468 creator A5060859207 @default.
• W4367296468 creator A5063535543 @default.
• W4367296468 date "2023-04-25" @default.
• W4367296468 modified "2023-10-14" @default.
• W4367296468 title "Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study (P9-12.006)" @default.
• W4367296468 doi "https://doi.org/10.1212/wnl.0000000000202059" @default.
• W4367296468 hasPublicationYear "2023" @default.
• W4367296468 type Work @default.
• W4367296468 citedByCount "0" @default.
• W4367296468 crossrefType "proceedings-article" @default.
• W4367296468 hasAuthorship W4367296468A5001453416 @default.
• W4367296468 hasAuthorship W4367296468A5018036182 @default.
• W4367296468 hasAuthorship W4367296468A5031918001 @default.
• W4367296468 hasAuthorship W4367296468A5032171459 @default.
• W4367296468 hasAuthorship W4367296468A5054082461 @default.
• W4367296468 hasAuthorship W4367296468A5055769971 @default.
• W4367296468 hasAuthorship W4367296468A5060859207 @default.
• W4367296468 hasAuthorship W4367296468A5063535543 @default.
• W4367296468 hasConcept C126322002 @default.
• W4367296468 hasConcept C142724271 @default.
• W4367296468 hasConcept C168563851 @default.
• W4367296468 hasConcept C187212893 @default.
• W4367296468 hasConcept C199360897 @default.
• W4367296468 hasConcept C204787440 @default.
• W4367296468 hasConcept C27081682 @default.
• W4367296468 hasConcept C2778029271 @default.
• W4367296468 hasConcept C2778541695 @default.
• W4367296468 hasConcept C3017807917 @default.
• W4367296468 hasConcept C3019800554 @default.
• W4367296468 hasConcept C41008148 @default.
• W4367296468 hasConcept C42219234 @default.
• W4367296468 hasConcept C71924100 @default.
• W4367296468 hasConceptScore W4367296468C126322002 @default.
• W4367296468 hasConceptScore W4367296468C142724271 @default.
• W4367296468 hasConceptScore W4367296468C168563851 @default.
• W4367296468 hasConceptScore W4367296468C187212893 @default.
• W4367296468 hasConceptScore W4367296468C199360897 @default.
• W4367296468 hasConceptScore W4367296468C204787440 @default.
• W4367296468 hasConceptScore W4367296468C27081682 @default.
• W4367296468 hasConceptScore W4367296468C2778029271 @default.
• W4367296468 hasConceptScore W4367296468C2778541695 @default.
• W4367296468 hasConceptScore W4367296468C3017807917 @default.
• W4367296468 hasConceptScore W4367296468C3019800554 @default.
• W4367296468 hasConceptScore W4367296468C41008148 @default.
• W4367296468 hasConceptScore W4367296468C42219234 @default.
• W4367296468 hasConceptScore W4367296468C71924100 @default.
• W4367296468 hasLocation W43672964681 @default.
• W4367296468 hasOpenAccess W4367296468 @default.
• W4367296468 hasPrimaryLocation W43672964681 @default.
• W4367296468 hasRelatedWork W1595546368 @default.
• W4367296468 hasRelatedWork W2017260580 @default.
• W4367296468 hasRelatedWork W2032318568 @default.
• W4367296468 hasRelatedWork W2741972252 @default.
• W4367296468 hasRelatedWork W2748952813 @default.
• W4367296468 hasRelatedWork W2899084033 @default.
• W4367296468 hasRelatedWork W3015196600 @default.
• W4367296468 hasRelatedWork W3042127684 @default.
• W4367296468 hasRelatedWork W4210761007 @default.
• W4367296468 hasRelatedWork W4246436659 @default.
• W4367296468 isParatext "false" @default.
• W4367296468 isRetracted "false" @default.
• W4367296468 workType "article" @default.